Drug Profile
Plixorafenib - Daiichi Sankyo Company
Alternative Names: FORE 8394; PLX-8394Latest Information Update: 30 Apr 2024
Price :
$50
*
At a glance
- Originator Plexxikon
- Developer Daiichi Sankyo Company; Fore Biotherapeutics; Plexxikon
- Class Antineoplastics; Cyclopropanes; Fluorobenzenes; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; Small molecules; Sulfonamides
- Mechanism of Action Proto oncogene protein b raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II CNS cancer; Solid tumours
- Discontinued Hairy cell leukaemia; Malignant melanoma
Most Recent Events
- 24 Apr 2024 Fore Biotherapeutics plans a phase I pharmacokinetics and safety trial (In volunteers) in USA (PO) (NCT06385119)
- 12 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by FORE Biotherapeutics
- 10 Apr 2024 Updated interim efficacy data from a phase I/IIa trial in Solid tumours released by FORE Biotherapeutics